Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: dividing (101), separating (322)

Nivolumab 480mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its marketing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its marketing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Pembrolizumab (200mg)

Description: Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab_240mg

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous cell
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Pembrolizumab (400mg) head and neck

Description: Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (400mg) Regimen • Head and Neck – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-400mg-head-and-neck.pdf

Pembrolizumab(400mg)

Description: Chemotherapy Protocol COLORECTAL CANCER Pembrolizumab (400mg) Regimen • Colorectal – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in adult patients with metastatic colorectal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Pembrolizumab400mg.pdf

Nivolumab

Description: Chemotherapy Protocol GASTRIC CANCER Nivolumab Regimen • Gastric Cancer – Nivolumab Indication • The treatment of advanced gastric or gastro-oesophageal junction cancer refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Nivolumab.pdf

Enfortumab-Vedotin-Pembrolizumab

Description: Chemotherapy Protocol UROTHELIAL CANCER Enfortumab vedotin-Pembrolizumab (EV-P) Regimen • Urothelial – Enfortumab vedotin - Pembrolizumab Indication • First-line treatment of adult patients
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Enfortumab-Vedotin-Pembrolizumab.pdf

MDT Leaflet_Young Lives vs Cancer Eligibility Criteria 2021

Description: YOUNG LIVES VS CANCER ELIGIBILITY FOR HEALTH PROFESSIONALS YOUNG LIVES VS CANCER: WHO WE ARE Cancer is shocking, overwhelming, isolating... and
Url: /Media/UHS-website-2019/Docs/Services/Cancer-care/mdt-leaflet-young-lives-vs-cancer-eligibility-criteria-2021.pdf

31 to 40 of 89

Previous … 2 3 4 5 6 … Next